BRAF and melanoma: Combined, ipilimumab and nivolumab extended progression-free survival by 8.5 and 4.5 months as compared with monotherapy with ipilimumab or nivolumab, respectively, and the FDA recently approved the combination for melanoma in the first-line setting for BRAF wild-type patients or following BRAF resistance.